Suzanne Winter: Yes, that’s a great question. I think we’re seeing it more and more. We’re also seeing centers that are starting to get the combination of the CyberKnife and the Radixact. And I think that, that is a commercial strategy that our teams are showing how our sites can really build up their patient referrals, how they can build their business by having this combination of a radiosurgery system in the CyberKnife but also a workhorse system like the Radixact. So I think we’re going to continue to see it more and more. But we’re absolutely thrilled with the center in Munich, primarily because they’re very well known for radiosurgery. The first system was really bought for intracranial type of applications and he is buying the second system now for more extra cranial more full body SBRT type of applications. And so again, we think it’s a strong endorsement and a site that we can use for strategic reference.
Neil Chatterji: Maybe just one follow-up here. So regarding kind of the customer installation delays or the aged outs. Just curious if there’s any updated insight on the construction environment, whether that’s related to worker shortages or supply issues? Just any update there?
Suzanne Winter: Yes. No, I think that’s a great question. I would say the aged out is really driven largely by systems that we had in the backlog that are in Russia that have aged out, still orders that we hope will go to installation. But because of the timing and what’s going on there, it have aged out. Also, I think that in general, COVID had an impact on the length of time for some of our backlog. We are firmly focused on our new orders, trying to put it through the lengths of orders that we believe will go to installation within 30 months so that we don’t have this sort of dynamic. But I would say, in general, we’re not seeing increased length of time for installations. And I think it’s very region independent. But there’s some good research that is out there on the capital equipment spend.
And I think that there’s a couple of key catalysts. One, radiation oncology is a revenue generator for the hospital. So it’s well positioned for priority and capital equipment spent. It’s also a strategic service line oncology, the key care area. And then the third is there is a large replacement market opportunity and in that research that was done, how old the equipment seems to be a key — one of the key points of prioritization of capital equipment funds. So again, we think that that will drive priority amongst the installation dollars that are needed.
Operator: Our next question comes from Brooks O’Neil with Lake Street Capital Markets.
Brooks O’Neil: And congratulations on what I think is a terrific quarter under the circumstances. I have — I am pleased to hear you talk about competitive wins, Suzanne and I wonder if you could just amplify a little bit on sort of what you think the dynamics are that are leading to competitive wins and not necessarily expecting you to call out the victims but if you could just highlight what you think is leading to your wins versus established competitors, that would be great.
